Research programme: growth hormone-releasing hormone agonists - Biscayne Pharmaceuticals

Drug Profile

Research programme: growth hormone-releasing hormone agonists - Biscayne Pharmaceuticals

Alternative Names: BIS-5409; GHRH agonists - Biscayne; MR-409

Latest Information Update: 23 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Miami
  • Developer Biscayne Pharmaceuticals
  • Class Hypothalamic hormones
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Myocardial infarction; Type 1 diabetes mellitus

Most Recent Events

  • 20 Oct 2015 Preclinical trials in Type-1 diabetes mellitus in USA (unspecified route)
  • 20 Oct 2015 Preclinical pharmacodynamics data in Type 1 diabetes mellitus released by Biscayne Pharmaceuticals
  • 21 May 2014 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top